Mangalam Drugs & Organics Limited has announced a change in the date of its upcoming Board of Directors meeting. The meeting, originally scheduled for November 13, 2025, has been postponed to November 20, 2025, due to unavoidable circumstances.

Key Points of the Rescheduled Meeting

The Board meeting agenda includes several important items:

1. Consideration and approval of un-audited financial results for the quarter ended September 30, 2025
2. Acknowledgment of the resignation of Mr. Ajay Avinash Samant, the company's Chief Financial Officer (CFO)
3. Other business items as per the agenda

Trading Window Closure

In line with regulatory requirements, Mangalam Drugs and Organics has implemented a trading window closure for share dealings. The details are as follows:

This temporary restriction on share dealings is a standard practice to prevent insider trading and ensure fair market practices during sensitive periods such as financial result announcements.

The postponement of the board meeting and the ongoing trading window closure highlight the company's commitment to regulatory compliance and transparent communication with its stakeholders. Investors and market participants are advised to take note of these changes and await the official announcement of the quarterly financial results.

Mangalam Drugs & Organics Limited (MDOL) has taken a significant step forward in its corporate restructuring plans. The company recently received a certified true copy of an order from the National Company Law Tribunal (NCLT) Mumbai Bench, admitting a petition for a scheme of merger by absorption.

Key Details of the Merger Scheme

The merger scheme involves the following entities:

• Mangalam Laboratories Private Limited
• Shri JB Pharma Private Limited
• Mangalam Drugs and Organics Limited

NCLT Proceedings

• Petition Presentation Date: September 23, 2025
• Admitting Bench: NCLT Bench-III
• Bench Members:
  • Ms. Lakshmi Gurung (Member Judicial)
  • Sh. Hariharan Neelakanta Iyer (Member Technical)
• Final Hearing Date: December 16, 2025

Regulatory Notifications

The NCLT has directed notices to be issued to various statutory authorities, including:

• Central Government
• Income Tax Authorities
• Reserve Bank of India
• Securities and Exchange Board of India
• Other relevant regulators

These authorities have been given 30 days to submit their representations regarding the merger scheme.

Next Steps

MDOL has committed to keeping the stock exchanges informed of any further material developments in this matter. The company will need to await the final hearing scheduled for December 16, 2025, where the NCLT will consider the merger scheme for final approval.

Implications for Investors

While the admission of the petition is a positive step towards the company's restructuring plans, investors should note that the final approval is still pending. The outcome of the merger could potentially impact the company's operations, financial structure, and market position.

Mangalam Drugs and Organics Limited continues to demonstrate its commitment to transparency by promptly disclosing this development to the stock exchanges. Investors and stakeholders are advised to keep a close watch on further announcements as the merger process progresses.